Drug Trial Radar · NCT00924989
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Dec 1, 2009
Primary completion
Jul 11, 2012
Study completion Oct 8, 2012
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 19, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens
Conditions
- Adrenocortical Carcinoma
Interventions
OSI-906Drug
Administered orally
PlaceboOther
Matching placebo administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival of single agent OSI-906 versus placeboTime frame: 33 months
Locations
35 sites in 9 countries. Site status is shown where the registry gives one.
TGen Clinical Research Service at Scottsdale Healthcare
Scottsdale, Arizona
University of Southern California
Los Angeles, California
UCLA
Los Angeles, California
University of Colorado Denver Cancer Center
Aurora, Colorado
University of Miami
Miami, Florida
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Dartmouth Medical School
Lebanon, New Hampshire
Duke Clinical Cancer Trials Services
Durham, North Carolina
Ohio State University
Columbus, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
Mary Crowley Cancer Research Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Royal North Shore Hospital Department of Endocrinology
St Leonards, New South Wales, Australia
St. Joseph's Hospital
Hamilton, Ontario, Canada
PMH - Princess Margaret Hospital
Toronto, Ontario, Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
CHRU Lille, Clinique Endocrinologique Marc Linquette
Lille, France
Centre Léon Bérard
Lyon, France
Institut Paoli-Calmettes
Marseille, France
Hôpital Cochin-Saint Vincent de Paul
Paris, France
CHU Bordeaux - Hôpital Haut-Lévêque
Pessac, France
Institut Gustave Roussy
Villejuif, France
Charite Universitaetsmedizin
Berlin, Germany
LMU München
Munich, Germany
Universitaets Klinikum Wuerzburg
Würzburg, Germany
Universita di Torino
Orbassano, Italy
Università Cattolica del Sacro Cuore
Rome, Italy
Academic Medical Center
Amsterdam, Netherlands
Maxima Medisch Centrum (MMC)
Eindhoven, Netherlands
Erasmus MC Rotterdam
Rotterdam, Netherlands
Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie Oddzial w Gliwicach
Gliwice, Poland
St. James' University hospital
Leeds, United Kingdom
Royal Marsden NHS Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.